Implications of GLP-1 receptor agonists for the fertility of women with polyendocrine metabolic ovarian syndrome.
Where this comes from
- Record sourced from PubMed, PMID 42710489.
- Also identified by DOI 10.1016/j.cmet.2026.08.013.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Women with polyendocrine metabolic ovarian syndrome (PMOS) represent a particularly challenging patient population, characterized by the convergence of reproductive dysfunction, obesity, insulin resistance, and chronic inflammation. The emergence of glucagon-like peptide-1 receptor agonists (GLP-1RAs) offers a transformative therapeutic opportunity, addressing the complex endocrine and reproductive disturbances that underpin this disorder.